Category Research

Merz Therapeutics Enrolls First Patients in Phase III Trials of XEOMIN® for Migraine Prevention

Merz Therapeutics Advances Migraine Research With Enrollment of First Patients in Two Global Phase III Clinical Trials for XEOMIN® (incobotulinumtoxinA) Merz Therapeutics GmbH, a neurology-focused specialty pharmaceutical company, announced a significant advancement in its clinical research program with the enrollment…

Read MoreMerz Therapeutics Enrolls First Patients in Phase III Trials of XEOMIN® for Migraine Prevention
SMSbiotech

SMSbiotech Launches First-in-Human Phase 1 Clinical Trial Targeting COPD

SMSbiotech Advances to First-in-Human Phase 1 Clinical Trial for COPD with Innovative Stem Cell Therapy San Diego-based regenerative medicine company begins groundbreaking trial in Australia, aiming to restore lung function in millions of patients worldwide. SMSbiotech, a biotechnology company headquartered…

Read MoreSMSbiotech Launches First-in-Human Phase 1 Clinical Trial Targeting COPD

NEJM to Publish Savara’s Phase 3 IMPALA-2 Trial Results in Autoimmune PAP

Savara’s Landmark IMPALA-2 Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis to Be Published in The New England Journal of Medicine Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to advancing therapies for rare respiratory diseases,…

Read MoreNEJM to Publish Savara’s Phase 3 IMPALA-2 Trial Results in Autoimmune PAP

Develop Health Secures $14.3M to Streamline Prior Authorization and Drug Access with GenAI

Develop Health Raises $14.3 Million Series A to Automate Prior Authorization and Medication Access with Generative AI Develop Health, a fast-growing healthcare technology company focused on modernizing benefits verification and prior authorization, announced today that it has raised $14.3 million…

Read MoreDevelop Health Secures $14.3M to Streamline Prior Authorization and Drug Access with GenAI

Scipher Medicine Unveils AI Platform to Predict Clinical Trial Failure

Scipher Medicine Launches ClinicalTrialRank.com: AI-Powered Platform to Predict Clinical Trial Failure and Transform Drug Development Strategy Scipher Medicine, a pioneering company in precision immunology and network medicine, has officially announced the public launch of ClinicalTrialRank.com, a first-of-its-kind artificial intelligence (AI)…

Read MoreScipher Medicine Unveils AI Platform to Predict Clinical Trial Failure
Rocket

Rocket Pharmaceuticals Cleared to Resume Phase 2 RP-A501 Study in Danon Disease

Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Pivotal Phase 2 Trial of RP-A501 in Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a diverse pipeline of genetic therapies for rare and devastating disorders,…

Read MoreRocket Pharmaceuticals Cleared to Resume Phase 2 RP-A501 Study in Danon Disease
MedImpact

MedImpact Launches Low-Cost Ustekinumab-aekn Biosimilar Nationwide

MedImpact Unveils Affordable Access to Unbranded Ustekinumab-aekn Biosimilar, Reshaping Specialty Pharmacy Market MedImpact Holdings Inc., the nation’s largest independent pharmacy benefit and healthcare solutions provider, announced a major step toward addressing escalating specialty drug costs with the launch of access…

Read MoreMedImpact Launches Low-Cost Ustekinumab-aekn Biosimilar Nationwide

jCyte Begins Patient Treatment in Phase JC02-88 Clinical Trial for Retinitis Pigmentosa

jCyte Marks Major Milestone with First Patients Treated in JC02-88 Clinical Trial Evaluating jCell for Retinitis Pigmentosa jCyte, Inc., a clinical-stage biotechnology company pioneering cell-based therapies for retinal diseases, announced a pivotal advancement in its development program: the enrollment and…

Read MorejCyte Begins Patient Treatment in Phase JC02-88 Clinical Trial for Retinitis Pigmentosa

RenovoRx Posts Q2 2025 Growth, Phase III Trial Cleared to Continue

RenovoRx Reports Strong Q2 2025 Revenue Growth and Receives Positive Independent Committee Recommendation to Continue Phase III TIGeR-PaC Trial RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage life sciences company pioneering targeted oncology drug delivery therapies, announced financial results for the second…

Read MoreRenovoRx Posts Q2 2025 Growth, Phase III Trial Cleared to Continue

ScaleReady Awards G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory

ScaleReady Awards $300,000 G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory to Advance Modular CAR T-Cell Manufacturing ScaleReady, a joint venture formed by Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, today announced that the Translational Sciences Laboratory at the Gates…

Read MoreScaleReady Awards G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory